List of Excipients in Branded Drug METHOTREXATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Accord Healthcare Inc	METHOTREXATE	methotrexate	16729-516	SODIUM HYDROXIDE
Rebel Distributors Corp	METHOTREXATE	methotrexate	42254-110	LACTOSE
Rebel Distributors Corp	METHOTREXATE	methotrexate	42254-110	MAGNESIUM STEARATE
Rebel Distributors Corp	METHOTREXATE	methotrexate	42254-110	STARCH, CORN
A-S Medication Solutions	METHOTREXATE	methotrexate	50090-0294	LACTOSE MONOHYDRATE
A-S Medication Solutions	METHOTREXATE	methotrexate	50090-0294	MAGNESIUM STEARATE

Generic Drugs Containing METHOTREXATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	methotrexate	0143-9367	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	methotrexate	0143-9367	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	methotrexate	0143-9519	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	methotrexate	0143-9519	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	methotrexate	0143-9519	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	methotrexate	0143-9830	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in METHOTREXATE?

# Of NDCs	Excipient
19	ANHYDROUS LACTOSE
3	BENZYL ALCOHOL
19	CELLULOSE, MICROCRYSTALLINE
5	FD&C RED NO. 40
13	HYDROCHLORIC ACID
1	HYDROXYPROPYL METHYLCELLULOSE

Methotrexate Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Methotrexate is a mature, low-cost active pharmaceutical ingredient with limited value in conventional tablet markets and greater commercial potential in differentiated delivery systems. The strongest opportunities are preservative-free injectable products, low-dose oral liquids, prefilled subcutaneous devices, pediatric formulations, stability-enhanced products, and formulations designed to reduce dosing errors.

The core excipient strategy should prioritize chemical stability, dose uniformity, tolerability, container compatibility, and administration convenience. Broad composition-of-matter exclusivity is unavailable. Commercial protection must come from formulation performance, device integration, manufacturing know-how, regulatory exclusivity, trademarks, and distribution execution.

What is the current FDA regulatory status of methotrexate?

Methotrexate is an FDA-approved antimetabolite used in oncology, rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis, and other immune-mediated conditions. It is available in oral tablets, injectable solutions, prefilled autoinjectors, and other parenteral presentations.

Product type	Typical route	Primary commercial use	Regulatory position
Methotrexate tablets	Oral	Oncology and chronic inflammatory disease	Generic market
Methotrexate sodium injection	Intravenous, intramuscular, subcutaneous	Oncology and hospital use	Generic and branded presentations
Prefilled injection or autoinjector	Subcutaneous	Rheumatology and dermatology	Differentiated branded products
Oral solution or compounded liquid	Oral	Pediatric and swallowing-impaired patients	Limited commercial availability relative to tablets
Preservative-free injection	Parenteral	Oncology, pediatrics, intrathecal or specialized use	Product-specific demand

FDA-approved methotrexate products carry important labeling controls because dosing errors can cause fatal toxicity. Weekly administration is common in rheumatology, while oncology regimens may be daily, intermittent, or protocol-specific. Product design must make the dosing schedule explicit and reduce the possibility of accidental daily administration.

The principal regulatory reference points are FDA product labeling, the Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, and product-specific FDA approval records.[1][2]

What excipients are used in methotrexate products?

Methotrexate excipients vary by dosage form, concentration, preservative status, and manufacturer. The most common tablet excipients include lactose or other diluents, starch-based disintegrants, and magnesium stearate. Injectable formulations generally use water for injection, sodium chloride for tonicity, and pH adjusters such as sodium hydroxide or hydrochloric acid.

Representative excipient functions

Excipient category	Typical function	Methotrexate formulation issue
Lactose or mannitol	Diluent and bulking agent	Patient tolerance, moisture control, tablet size
Microcrystalline cellulose	Diluent and compression aid	Useful for direct compression and low-dose uniformity
Corn starch or sodium starch glycolate	Disintegration	Controls tablet breakup and dissolution
Magnesium stearate	Lubricant	Excess can slow dissolution
Sodium chloride	Isotonicity adjustment	Useful in injectable solutions
Sodium hydroxide or hydrochloric acid	pH adjustment	Controls solubility and degradation
Benzyl alcohol or other preservatives	Multidose antimicrobial protection	Toxicity and age restrictions, especially in neonates and young children
Polysorbates or surfactants	Solubilization or interfacial protection	Potential oxidation and compatibility concerns
Antioxidants or chelators	Chemical stability	Must be justified through degradation studies
Flavor systems and sweeteners	Palatability	Particularly important for pediatric oral liquids

Methotrexate is a potent, low-dose drug. A small change in blend uniformity, segregation behavior, or tablet weight can produce a clinically relevant dose variation. Excipient selection therefore has a direct relationship to product safety rather than being a purely manufacturing decision.

How does methotrexate stability affect excipient selection?

Methotrexate stability depends on pH, temperature, light exposure, concentration, oxygen exposure, container composition, and sterilization conditions. The formulation program should characterize both methotrexate degradation and the formation of related substances under real storage and administration conditions.

Key development controls include:

1. Selecting a pH range that balances solubility and chemical stability.
2. Limiting exposure to light where photostability data indicate risk.
3. Evaluating oxygen transfer through containers and closures.
4. Testing adsorption or absorption into tubing, syringes, elastomers, and administration sets.
5. Controlling particulate formation in concentrated injectable products.
6. Assessing compatibility with common infusion diluents.
7. Establishing in-use stability after vial puncture, syringe transfer, or device activation.

For injectable products, the container-closure system can be as commercially important as the excipient package. A low-extractables syringe, siliconization strategy, compatible needle, and stable plunger system can support product differentiation even when the active ingredient and core excipients are conventional.

What formulation patents protect methotrexate products?

Methotrexate composition-of-matter protection has expired. The relevant intellectual-property value is concentrated in formulation, device, manufacturing, packaging, and method-of-use claims.

Potentially protectable categories include:

• Concentrated methotrexate solutions with defined pH and impurity profiles.
• Preservative-free multidose or single-use presentations.
• Stable liquid formulations with specified excipient ratios.
• Prefilled syringes and autoinjectors.
• Needle-shield and dose-delivery mechanisms.
• Low-volume subcutaneous formulations.
• Oral liquids with taste-masking systems.
• Pediatric dosage forms with dose selectors or calibrated delivery devices.
• Lyophilized products with defined reconstitution performance.
• Manufacturing processes that reduce degradation or particulates.
• Packaging systems that protect against light or oxygen.
• Methods of reducing medication errors through labeled weekly dosing systems.

Patent strength depends on the claim scope, prosecution history, prior art, enablement, and whether the formulation produces measurable advantages over known methotrexate solutions or tablets. A claim covering methotrexate, water, sodium chloride, and pH adjustment alone is likely to face substantial obviousness and anticipation pressure. Stronger protection would require a defined concentration range, excipient relationship, impurity profile, device feature, stability result, or clinical-use advantage.

When does methotrexate lose exclusivity?

Methotrexate lost foundational exclusivity decades ago. Generic tablets and injectable products are widely available, and the core active ingredient does not support a new chemical entity exclusivity strategy.

Branded presentations have obtained narrower periods of regulatory protection based on their specific approval pathways. Those periods do not restore exclusivity for methotrexate itself. They protect the approved product, labeling, formulation, or device for the applicable statutory period.

Exclusivity category	Methotrexate position
New chemical entity exclusivity	Expired
Core composition-of-matter patent	Expired
Generic tablet entry	Established
Generic injectable entry	Established
Device or formulation exclusivity	Product-specific and limited
Orphan exclusivity	Not a general methotrexate market protection
Pediatric exclusivity	Product-specific if awarded; not a core market barrier

A company commercializing a new methotrexate product should assume that regulatory exclusivity will be short or unavailable unless the product qualifies for a specific pathway. The business case should rely on product performance, supply reliability, prescriber preference, payer positioning, and device differentiation.

What is the Orange Book status of methotrexate?

The Orange Book contains product-specific patent and therapeutic-equivalence information for FDA-approved drug products. Methotrexate tablets and injections are represented through multiple approved products and manufacturers, while branded delivery systems may have separate listings and product identifiers.[1]

Orange Book analysis should distinguish:

• Methotrexate tablets from methotrexate sodium injection.
• Immediate-release products from specialized delivery systems.
• Drug patents from device patents.
• Listed patents from enforceable patents.
• Product-specific labeling claims from broad disease-treatment claims.
• Approved strengths and routes from unapproved compounding practices.

The presence of an Orange Book patent does not establish that the patent will block all generic entry. A generic applicant may file a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed. Patent listing practices and status can change, so commercial diligence should use the current FDA database and the relevant patent records.

Which companies are competing in the methotrexate market?

Competition is divided between low-cost generic suppliers and branded products that sell administration convenience.

Generic manufacturers

Generic methotrexate is supplied by multiple manufacturers and distributors. Competition typically focuses on:

• Lowest acquisition cost.
• Reliable hospital supply.
• Injectable presentation availability.
• Preservative-free status.
• Shortage resilience.
• Contract-manufacturing capacity.
• Ability to support oncology and specialty-pharmacy channels.

Branded delivery-system companies

Products such as Otrexup, Rasuvo, and RediTrex established commercial models around subcutaneous administration rather than active-ingredient differentiation. Their value proposition has included simplified self-administration, premeasured dosing, reduced handling, and use in patients who cannot tolerate or adequately absorb oral therapy.[3][4][5]

The commercial challenge is that branded devices compete against inexpensive tablets, generic vials, multidose syringes, and increasingly familiar specialty-pharmacy injection workflows. A new product must demonstrate a meaningful benefit in adherence, persistence, administration confidence, caregiver burden, or total treatment cost.

What formulation opportunities exist for methotrexate?

Pediatric oral liquid

A ready-to-use oral liquid is one of the clearest unmet formulation opportunities. Pediatric patients may have difficulty swallowing tablets, and compounded liquids can vary in concentration, flavor, stability, and measuring-device accuracy.

A differentiated product could include:

• A low-concentration option for precise pediatric dosing.
• A higher-concentration option to reduce administration volume.
• A child-resistant bottle.
• An oral syringe with a dose-specific marking system.
• Taste masking without excessive sugar.
• Defined in-use stability after opening.
• A formulation compatible with feeding tubes.
• Clear weekly dosing instructions.

The primary development risk is methotrexate taste. Sweeteners alone may not sufficiently mask bitterness or chemical aftertaste. Polymer-based taste masking, ion-exchange systems, lipid-compatible flavor systems, or multiparticulate approaches could create a stronger product profile, but each adds regulatory and manufacturing complexity.

Preservative-free injectable product

Preservative-free methotrexate can address hospital, pediatric, oncology, and specialty-care demand. The product may be supplied in single-dose vials, prefilled syringes, or cartridges.

Commercial advantages may include:

• Reduced concern about benzyl alcohol exposure.
• Better suitability for vulnerable populations.
• Fewer preparation steps.
• Lower contamination risk.
• Improved compatibility with institutional protocols.
• Easier inventory management.

The opportunity is strongest where the product solves a procurement or administration problem rather than merely removing an excipient. Preservative-free status alone may not support a premium if comparable products are already available.

Low-volume subcutaneous injection

A concentrated, low-volume formulation can support autoinjector or prefilled-pen delivery. The formulation must maintain acceptable viscosity, syringeability, injection force, chemical stability, and dose accuracy.

Excipient work should evaluate:

• Buffer capacity.
• Osmolality.
• Viscosity at refrigerated and room temperatures.
• Silicone oil interaction.
• Needle gauge and injection time.
• Plunger glide force.
• Extractables and leachables.
• Device hold time after removal from refrigeration.

A product that reduces injection time and device complexity may compete more effectively than a formulation that only changes concentration.

Oral solid-dose adherence products

Methotrexate tablets are inexpensive, but they have a high medication-error profile because many chronic inflammatory-disease regimens are weekly. Commercial opportunities include:

• Calendar blister packs.
• Weekly unit-dose cards.
• Tablets with distinct strength coding.
• Packaging that separates current-week and next-week doses.
• Integrated patient instructions.
• Specialty-pharmacy dispensing systems.
• Digital adherence support linked to the package.

Packaging patents and human-factors data may provide more defensible protection than a conventional tablet composition.

What method-of-use patents affect methotrexate?

Methotrexate method-of-use patents generally concern treatment regimens, combination therapy, route of administration, dosing schedules, or patient populations. Older therapeutic uses are generally difficult to protect because methotrexate has been used extensively across oncology and inflammatory diseases.

Potentially stronger opportunities may involve:

• Defined low-dose regimens for a specific patient population.
• Combination therapy with a newer biologic or targeted therapy.
• Biomarker-selected treatment.
• Treatment protocols that reduce toxicity.
• Structured folate supplementation regimens.
• Device-enabled weekly administration.
• Route-specific use in patients unable to use oral therapy.

Method-of-use protection is vulnerable to prescribing-label limitations, prior clinical use, off-label practice, and divided infringement issues. It is more valuable when paired with a branded formulation, dosing device, specialty-pharmacy protocol, or diagnostic selection strategy.

Are there Paragraph IV challenges or methotrexate patent settlements?

Generic methotrexate entry is already established. The market does not depend on a single unexpired active-ingredient patent or a single originator-controlled patent thicket.

Paragraph IV activity may arise around branded autoinjectors, delivery systems, or specific formulation patents. Such challenges are product-specific rather than representative of the overall methotrexate market. A Paragraph IV filing can trigger a Hatch-Waxman litigation period, but the commercial impact depends on the patents listed for the reference product and the strength of the asserted claims.[6]

No settlement should be treated as commercially material without confirming:

• The specific patent numbers.
• The NDA and ANDA involved.
• The agreed generic launch date.
• Any authorized-generic rights.
• Royalty terms.
• Restrictions on formulation or device substitution.
• Whether the settlement was reviewed under FTC reporting requirements.

For investment analysis, a settlement involving a branded autoinjector may affect one delivery platform without changing generic tablet or vial competition.

Is there biosimilar risk for methotrexate?

Methotrexate is a small-molecule chemical drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. The relevant competitors are generic drug products, 505(b)(2) products, drug-device combinations, and specialty formulations.

This distinction matters commercially. A methotrexate developer does not need to manage biosimilar interchangeability, reference-biologic switching, or biologic manufacturing comparability. It does need to manage:

• ANDA bioequivalence.
• Injectable quality and sterility.
• Device performance.
• Human-factors validation.
• Formulation sameness or suitability for a 505(b)(2) pathway.
• Labeling differences.
• Pediatric and specialty-use requirements.

How strong is the methotrexate patent estate?

The overall methotrexate patent estate is weak for the active ingredient and potentially moderate for selected delivery systems.

IP category	Relative strength	Commercial assessment
Active ingredient	Very weak	Foundational protection expired
Conventional tablet	Weak	Low barriers and established generic competition
Standard injectable solution	Weak to moderate	Manufacturing and quality barriers exceed patent barriers
Pediatric liquid	Moderate if differentiated	Taste, stability, device, and dosing claims may be available
Autoinjector	Moderate	Device and human-factors protection can support differentiation
Preservative-free presentation	Weak to moderate	Valuable commercially but often difficult to protect broadly
Packaging and adherence system	Moderate	Design and method claims may support niche exclusivity
Manufacturing process	Moderate	Trade secrets may be more durable than patents
Combination or biomarker use	Variable	Dependent on clinical data and prior art

Manufacturing know-how may provide the most durable practical barrier. Critical examples include impurity control, sterile filtration, concentration limits, container selection, low-temperature handling, and validated hold times.

What generic launch risks exist for methotrexate?

A conventional generic tablet launch faces low patent risk but high price and supply risk. A differentiated product faces greater execution risk.

Generic tablet launch

Expected characteristics include:

• Low development cost.
• Established bioequivalence pathway.
• Intense price competition.
• Limited prescriber loyalty.
• Vulnerability to wholesaler and group-purchasing pressure.
• Potential margin compression.

Generic injectable launch

The main risks are:

• Sterility failures.
• Supply interruptions.
• Container-closure defects.
• Particulate contamination.
• Hospital contract loss.
• Competition from established suppliers.
• Difficulties securing active pharmaceutical ingredient capacity.

Branded liquid or device launch

The main risks are:

• Insufficient payer coverage.
• High device manufacturing cost.
• Training requirements.
• Limited willingness to pay.
• Substitution by compounded products or generic vials.
• Patent challenges.
• Low switching rates among stable patients.

The strongest launch strategy is usually a narrow, high-value segment with a defined operational problem. Pediatric liquid and ready-to-administer subcutaneous products have clearer differentiation than another conventional tablet strength.

What licensing deals and partnering models are relevant?

Methotrexate licensing opportunities are more likely to involve delivery technology than the active ingredient. Relevant structures include:

• Licensing an autoinjector platform to a specialty-pharma company.
• Co-development of a pediatric oral liquid.
• Contract development and manufacturing for preservative-free injections.
• Regional rights for a branded prefilled syringe.
• Device supply agreements with minimum-volume commitments.
• Technology transfer for sterile fill-finish.
• Combination-product partnerships with specialty pharmacies.

A licensing agreement should allocate responsibility for device validation, pharmacovigilance, complaints, recalls, regulatory submissions, patent prosecution, and manufacturing changes. The economics will depend more on device ownership and channel access than on the cost of methotrexate itself.

What revenue exposure does methotrexate create?

Methotrexate is widely used but generally generates low revenue per tablet or vial. Revenue concentration is more attractive in differentiated formats:

Segment	Revenue potential	Margin potential	Main constraint
Standard tablets	High volume, low value	Low	Generic price competition
Hospital injection	Moderate volume	Low to moderate	Procurement pressure
Specialty injectable	Moderate volume	Moderate to high	Payer and device costs
Pediatric liquid	Niche volume	Moderate to high	Taste and stability
Autoinjector	Moderate volume	Higher	Device cost and competition
Adherence packaging	Add-on value	Moderate	Reimbursement and workflow adoption

Public companies generally do not disclose methotrexate revenue as a separate material segment. Financial modeling should use product-level prescription, unit, price, and channel data rather than company-wide revenue assumptions.

What geographic opportunities exist for methotrexate products?

The United States offers the clearest pathway for branded device and formulation products because of specialty-pharmacy infrastructure and FDA combination-product experience. Europe has demand for prefilled and patient-friendly administration systems, but country-level reimbursement and reference-pricing rules can limit premium pricing.

Emerging-market opportunities are more likely to favor:

• Stable oral liquids.
• Affordable tablets.
• Heat-tolerant packaging.
• Low-cost vials.
• Simple dose-measuring devices.
• Local sterile manufacturing.

A high-cost autoinjector may have limited uptake where patients and hospitals already use low-cost oral or vial-based therapy. Regional formulation and packaging requirements should be assessed separately because excipient acceptability, labeling, pediatric-use expectations, and device regulation vary by jurisdiction.

Key Takeaways

• Methotrexate has no meaningful remaining composition-of-matter exclusivity.
• Conventional tablets offer volume but limited margin and weak patent protection.
• The strongest commercial opportunities are pediatric oral liquids, preservative-free injections, concentrated subcutaneous products, and adherence-focused packaging.
• Excipient selection should prioritize stability, dose accuracy, tolerability, container compatibility, and administration safety.
• Methotrexate is not subject to biosimilar competition; generic and combination-product pathways are the relevant competitive frameworks.
• Device patents, formulation claims, manufacturing know-how, and human-factors data can create narrower but commercially useful barriers.
• A new product must solve a measurable administration, adherence, safety, or supply problem to justify a premium.
• Generic entry risk is high for conventional products and lower only where the formulation, device, or manufacturing process is difficult to replicate.
• Hospital injectable products are exposed to procurement pressure, while specialty devices are exposed to payer and substitution risk.
• The most defensible strategy is a differentiated presentation supported by clinical usability data, reliable supply, and a focused specialty channel.

FAQs

Can methotrexate be reformulated as a once-weekly tablet?

The active ingredient is already used in weekly regimens for inflammatory disease, but a once-weekly product would require careful dose-strength, labeling, packaging, and medication-error controls. Calendar packaging and explicit weekly instructions may provide more practical value than a new tablet excipient system.

Is a preservative-free methotrexate injection commercially attractive?

It can be attractive in pediatrics, oncology, hospitals, and settings where preservative exposure or multidose handling is a concern. The commercial case is strongest when preservative-free status is combined with a ready-to-use container or improved supply reliability.

Can a methotrexate oral liquid receive FDA approval?

Yes. A sponsor could pursue an ANDA, 505(b)(2), or another applicable pathway depending on the reference product, formulation differences, route, concentration, and bioequivalence strategy. The regulatory pathway must address stability, dosing accuracy, palatability, container compatibility, and measuring-device performance.

Are methotrexate autoinjectors protected by patents?

Some products may have patent protection covering formulation, delivery devices, cartridge systems, needle assemblies, dose mechanisms, or use methods. Protection must be reviewed product by product in FDA listings and the relevant patent databases.

What is the most attractive excipient opportunity in methotrexate?

A stable, palatable, ready-to-use pediatric oral liquid has a strong unmet-use-case profile. A low-volume preservative-free subcutaneous formulation with a simple autoinjector is the stronger opportunity for specialty-market pricing.

References

1. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

2. U.S. Food and Drug Administration. (n.d.). Methotrexate product labeling and prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2013). Otrexup approval package and prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2014). Rasuvo approval package and prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2018). RediTrex approval package and prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/

6. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Refuse-to-receive standards and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submissions